Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group.

Menasché P, Jamieson WR, Flameng W, Davies MK

The Journal of thoracic and cardiovascular surgery1 Oct 1995Cited by 27 (Europe PMC)

PMID7475138DOI10.1016/s0022-5223(05)80179-5PepBankPUB-07475138

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In high-risk coronary bypass patients, acadesine reduced Q-wave myocardial infarction incidence versus placebo.
In plain wordsIn high-risk coronary bypass patients, acadesine reduced Q-wave heart attacks compared with placebo.
Peptide
AICAR (acadesine)
Outcome
DecreaseQ-wave myocardial infarction, high-risk subgroup
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.1 mg/kg per minute intravenously and 5 micrograms/ml in cardioplegic solution · Intravenous infusion and cardioplegic solution · 7 hoursAs given in this study (human).
Measurements
Q-wave myocardial infarction incidence
10%
acadesine, high-risk patients
Q-wave myocardial infarction incidence
19.7%
placebo, high-risk patients
P value
0.032 NA
between groups
Source sentences
Summary
Acadesine did not significantly affect the incidence of myocardial infarction in the overall study population, but it significantly reduced the incidence of Q-wave myocardial infarction in high-risk patients (placebo, 19.7%; acadesine, 10.0%; p = 0.032).
3 context sentences(design, population, supporting numbers)
Summary · context
Although overall there were no statistically significant between-group differences for the primary study end points, a secondary analysis in a prospectively defined high-risk subgroup suggests that acadesine may be beneficial in some patients.
Summary · context
The effect of acadesine, an adenosine-regulating agent, on the incidence of myocardial infarction, all adverse cardiovascular outcomes (myocardial infarction, cardiac death, left ventricular dysfunction, life-threatening arrhythmia, or cerebrovascular accident) and mortality was assessed in 821 pati…
Summary · context
They were randomized in a double-blind manner to placebo (n = 418) or acadesine (n = 403) by intravenous infusion over 7 hours (0.1 mg/kg per minute) and in the cardioplegic solution (placebo or acadesine; 5 micrograms/ml).
Report a problemFND-0747513802
02HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, acadesine did not significantly affect myocardial infarction incidence versus placebo.
In plain wordsIn coronary bypass patients, acadesine did not significantly change heart attack rates compared with placebo.
Peptide
AICAR (acadesine)
Outcome
No significant changeMyocardial infarction, overall
Study
n = 821
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.1 mg/kg per minute intravenously and 5 micrograms/ml in cardioplegic solution · Intravenous infusion and cardioplegic solution · 7 hoursAs given in this study (human).
Source sentences
Summary
Acadesine did not significantly affect the incidence of myocardial infarction in the overall study population
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of acadesine, an adenosine-regulating agent, on the incidence of myocardial infarction, all adverse cardiovascular outcomes (myocardial infarction, cardiac death, left ventricular dysfunction, life-threatening arrhythmia, or cerebrovascular accident) and mortality was assessed in 821 pati…
Summary · context
They were randomized in a double-blind manner to placebo (n = 418) or acadesine (n = 403) by intravenous infusion over 7 hours (0.1 mg/kg per minute) and in the cardioplegic solution (placebo or acadesine; 5 micrograms/ml).
Report a problemFND-0747513801
03HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, all adverse cardiovascular outcomes were similar with acadesine and placebo.
In plain wordsIn coronary bypass patients, adverse heart and blood vessel outcomes were similar with acadesine and placebo.
Peptide
AICAR (acadesine)
Outcome
No significant changeAll adverse cardiovascular outcomes
Study
n = 821
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.1 mg/kg per minute intravenously and 5 micrograms/ml in cardioplegic solution · Intravenous infusion and cardioplegic solution · 7 hoursAs given in this study (human).
Measurements
Adverse cardiovascular outcomes
18.4%
acadesine
Adverse cardiovascular outcomes
19.4%
placebo
Source sentences
Summary
The incidences of all adverse cardiovascular outcomes (placebo, 19.4%; acadesine, 18.4%) and overall mortality (placebo, 3.4%; acadesine, 2.7%) were similar between the two treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of acadesine, an adenosine-regulating agent, on the incidence of myocardial infarction, all adverse cardiovascular outcomes (myocardial infarction, cardiac death, left ventricular dysfunction, life-threatening arrhythmia, or cerebrovascular accident) and mortality was assessed in 821 pati…
Summary · context
They were randomized in a double-blind manner to placebo (n = 418) or acadesine (n = 403) by intravenous infusion over 7 hours (0.1 mg/kg per minute) and in the cardioplegic solution (placebo or acadesine; 5 micrograms/ml).
Report a problemFND-0747513803
04HumanRandomized controlled trialSafety outcome
In coronary bypass patients, overall mortality was similar with acadesine and placebo.
In plain wordsIn coronary bypass patients, overall death rates were similar with acadesine and placebo.
Peptide
AICAR (acadesine)
Outcome
No significant changeOverall mortality
Study
n = 821
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
0.1 mg/kg per minute intravenously and 5 micrograms/ml in cardioplegic solution · Intravenous infusion and cardioplegic solution · 7 hoursAs given in this study (human).
Measurements
Overall mortality
2.7%
acadesine
Overall mortality
3.4%
placebo
Source sentences
Summary
The incidences of all adverse cardiovascular outcomes (placebo, 19.4%; acadesine, 18.4%) and overall mortality (placebo, 3.4%; acadesine, 2.7%) were similar between the two treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of acadesine, an adenosine-regulating agent, on the incidence of myocardial infarction, all adverse cardiovascular outcomes (myocardial infarction, cardiac death, left ventricular dysfunction, life-threatening arrhythmia, or cerebrovascular accident) and mortality was assessed in 821 pati…
Summary · context
They were randomized in a double-blind manner to placebo (n = 418) or acadesine (n = 403) by intravenous infusion over 7 hours (0.1 mg/kg per minute) and in the cardioplegic solution (placebo or acadesine; 5 micrograms/ml).
Report a problemFND-0747513804
05HumanRandomized controlled trialSafety outcome
In coronary bypass patients, acadesine reduced death incidence during the first 3 postoperative days versus placebo.
In plain wordsIn coronary bypass patients, acadesine reduced deaths during the first postoperative days compared with placebo.
Peptide
AICAR (acadesine)
Outcome
DecreaseDeath during first postoperative days
Study
n = 821
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
0.1 mg/kg per minute intravenously and 5 micrograms/ml in cardioplegic solution · Intravenous infusion and cardioplegic solution · 7 hoursAs given in this study (human).
Measurements
Early death incidence
0.2%
acadesine, first 3 postoperative days
Early death incidence
1.9%
placebo, first 3 postoperative days
P value
0.038 NA
between groups
Source sentences
Summary
However, acadesine reduced the incidence of cardiac related events that contributed to deaths occurring during the first 3 postoperative days so that the incidence of death in this period was lower (placebo, 1.9%; acadesine, 0.2%; p = 0.038).
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of acadesine, an adenosine-regulating agent, on the incidence of myocardial infarction, all adverse cardiovascular outcomes (myocardial infarction, cardiac death, left ventricular dysfunction, life-threatening arrhythmia, or cerebrovascular accident) and mortality was assessed in 821 pati…
Summary · context
They were randomized in a double-blind manner to placebo (n = 418) or acadesine (n = 403) by intravenous infusion over 7 hours (0.1 mg/kg per minute) and in the cardioplegic solution (placebo or acadesine; 5 micrograms/ml).
Report a problemFND-0747513806
06HumanRandomized controlled trialSafety outcome
In coronary bypass patients, no adverse events were related to acadesine treatment.
In plain wordsIn coronary bypass patients, the study linked no adverse events to acadesine treatment.
Peptide
AICAR (acadesine)
Outcome
Not applicableTreatment-related adverse events
Study
n = 403
Outcome group
Adverse events · Whole body
Studied dose
0.1 mg/kg per minute intravenously and 5 micrograms/ml in cardioplegic solution · Intravenous infusion and cardioplegic solution · 7 hoursAs given in this study (human).
Source sentences
Summary
No adverse events were related to acadesine treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of acadesine, an adenosine-regulating agent, on the incidence of myocardial infarction, all adverse cardiovascular outcomes (myocardial infarction, cardiac death, left ventricular dysfunction, life-threatening arrhythmia, or cerebrovascular accident) and mortality was assessed in 821 pati…
Summary · context
They were randomized in a double-blind manner to placebo (n = 418) or acadesine (n = 403) by intravenous infusion over 7 hours (0.1 mg/kg per minute) and in the cardioplegic solution (placebo or acadesine; 5 micrograms/ml).
Report a problemFND-0747513807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.